Efficacy of azacitidine is independent of molecular and clinical characteristics-an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature

Published 2018 View Full Article

Authors

Keywords

myelodysplastic syndromes; azacitidine; hypomethylating agents; response prediction; targeted therapy

Journal

Oncotarget

Volume 9, Issue 45, Pages -

Publisher

Impact Journals, LLC

Online

2018-06-11

DOI

10.18632/oncotarget.25328

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started